» Articles » PMID: 36768976

Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Feb 11
PMID 36768976
Authors
Affiliations
Soon will be listed here.
Abstract

Near infrared photoimmunotherapy (NIR-PIT) is a newly developed molecular targeted cancer treatment, which selectively kills cancer cells or immune-regulatory cells and induces therapeutic host immune responses by administrating a cancer targeting moiety conjugated with IRdye700. The local exposure to near-infrared (NIR) light causes a photo-induced ligand release reaction, which causes damage to the target cell, resulting in immunogenic cell death (ICD) with little or no side effect to the surrounding normal cells. Moreover, NIR-PIT can generate an immune response in distant metastases and inhibit further cancer attack by combing cancer cells targeting NIR-PIT and immune regulatory cells targeting NIR-PIT or other cancer treatment modalities. Several recent improvements in NIR-PIT have been explored such as catheter-driven NIR light delivery, real-time monitoring of cancer, and the development of new target molecule, leading to NIR-PIT being considered as a promising cancer therapy. In this review, we discuss the progress of NIR-PIT, their mechanism and design strategies for cancer treatment. Furthermore, the overall possible targeting molecules for NIR-PIT with their application for cancer treatment are briefly summarised.

Citing Articles

Targeted Elimination of Influenza Virus and Infected Cells with Near-Infrared Antiviral Photoimmunotherapy (NIR-AVPIT).

Mizukoshi T, Tateishi K, Tokusanai M, Yoshinaka Y, Yamamoto A, Yamamoto N Pharmaceutics. 2025; 17(2).

PMID: 40006540 PMC: 11859895. DOI: 10.3390/pharmaceutics17020173.


Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research.

Allen D, Szoo M, van Bergen T, Seppelin A, Oh J, Saad M Antib Ther. 2025; 8(1):68-85.

PMID: 39958565 PMC: 11826922. DOI: 10.1093/abt/tbaf001.


Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer.

Wolf I, Schultze-Seemann S, Gratzke C, Wolf P Antibodies (Basel). 2025; 14(1.

PMID: 39846613 PMC: 11755620. DOI: 10.3390/antib14010005.


Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.

Ding J, Yeong C Front Oncol. 2024; 14:1504139.

PMID: 39703856 PMC: 11655346. DOI: 10.3389/fonc.2024.1504139.


Near-infrared photoimmunotherapy in cancer treatment: a bibliometric and visual analysis.

Tian J, Chen C, Du X, Wang M Front Pharmacol. 2024; 15:1485242.

PMID: 39498336 PMC: 11533137. DOI: 10.3389/fphar.2024.1485242.


References
1.
Sasikumar P, Ramachandra M . Small-molecule antagonists of the immune checkpoint pathways: concept to clinic. Future Med Chem. 2017; 9(12):1305-1308. DOI: 10.4155/fmc-2017-0107. View

2.
Wakiyama H, Furusawa A, Okada R, Inagaki F, Kato T, Maruoka Y . Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy. Cancers (Basel). 2020; 12(12). PMC: 7763141. DOI: 10.3390/cancers12123747. View

3.
Nakajima T, Sano K, Choyke P, Kobayashi H . Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics. 2013; 3(6):357-65. PMC: 3677407. DOI: 10.7150/thno.5908. View

4.
Liu H, Zhao Z, Zhang L, Li Y, Jain A, Barve A . Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. J Immunother Cancer. 2019; 7(1):270. PMC: 6805442. DOI: 10.1186/s40425-019-0705-y. View

5.
Maennling A, Tur M, Niebert M, Klockenbring T, Zeppernick F, Gattenlohner S . Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers (Basel). 2019; 11(12). PMC: 6966464. DOI: 10.3390/cancers11121826. View